lamotrigine has been researched along with Deficiency, Mental in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the effects of lamotrigine as adjunctive therapy for refractory epilepsy in patients with mental retardation." | 9.10 | Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. ( Barrett, PS; FineSmith, R; Hammer, AE; McKee, JR; Sunder, TR; Varner, JA; Vuong, A, 2003) |
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 9.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| "Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome." | 9.08 | Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. ( Arvidsson, JF; Barrera, MN; Manasco, P; Motte, J; Mullens, EL; Trevathan, E, 1997) |
| "To determine whether the efficacy and tolerability of adjunctive lamotrigine differ as a function of whether persons with mental retardation and refractory epilepsy resided in institutions or the community." | 7.73 | Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuongc, A, 2006) |
| "To describe significant positive or negative psychotropic effects of lamotrigine (LTG) observed in epilepsy patients with mental retardation (MR)." | 7.70 | Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. ( Devinsky, O; Dhoon, A; Ettinger, AB; Kanner, A; Saracco, J; Weisbrot, DM, 1998) |
| "Lamotrigine (LTG) is a valuable addition to the medical management of epilepsy with wide spectrum of efficacy and good outcomes for quality of life." | 7.70 | Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. ( Beran, RG; Gibson, RJ, 1998) |
| "Fifty children and adolescents with intractable epilepsy were treated with lamotrigine." | 7.69 | Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. ( Bauzienè, R; Uvebrant, P, 1994) |
| "Falling due to startle-induced seizures (SISs) often leads to injury." | 5.37 | Lamotrigine is favourable for startle-induced seizures. ( Fujiwara, T; Ikeda, H; Imai, K; Inoue, Y; Shigematsu, H; Shishido, T; Takahashi, Y; Takayama, R, 2011) |
| "The syndrome is characterized by mental impairment, frequent seizures of multiple types that are particularly resistant to treatment, and high rates of seizure-related injury." | 5.36 | The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. ( Benedict, A; Maclaine, G; Verdian, L, 2010) |
| "Epilepsy is a major comorbid condition in adolescents with mental retardation and is often characterized by multiple seizure types that are refractory to treatment." | 5.33 | Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuong, A, 2006) |
| "Mean lamotrigine dose was 272 +/- 133 mg per day." | 5.31 | Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. ( Gidal, BE; Lott, RS; Marty, KJ; Rutecki, P; Shaw, R; Speth, J; Walker, JK, 2000) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "This study evaluated the effects of lamotrigine as adjunctive therapy for refractory epilepsy in patients with mental retardation." | 5.10 | Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. ( Barrett, PS; FineSmith, R; Hammer, AE; McKee, JR; Sunder, TR; Varner, JA; Vuong, A, 2003) |
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 5.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| "Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome." | 5.08 | Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. ( Arvidsson, JF; Barrera, MN; Manasco, P; Motte, J; Mullens, EL; Trevathan, E, 1997) |
| "To determine whether the efficacy and tolerability of adjunctive lamotrigine differ as a function of whether persons with mental retardation and refractory epilepsy resided in institutions or the community." | 3.73 | Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuongc, A, 2006) |
| "Lamotrigine (LTG) is a valuable addition to the medical management of epilepsy with wide spectrum of efficacy and good outcomes for quality of life." | 3.70 | Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. ( Beran, RG; Gibson, RJ, 1998) |
| "To describe significant positive or negative psychotropic effects of lamotrigine (LTG) observed in epilepsy patients with mental retardation (MR)." | 3.70 | Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. ( Devinsky, O; Dhoon, A; Ettinger, AB; Kanner, A; Saracco, J; Weisbrot, DM, 1998) |
| "Fifty children and adolescents with intractable epilepsy were treated with lamotrigine." | 3.69 | Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. ( Bauzienè, R; Uvebrant, P, 1994) |
| "This single case reports an open trial of lamotrigine in the treatment of self-injurious behavior (SIB) and epilepsy in an 18-year-old female diagnosed with generalized seizure disorder, stereotypic movement disorder, and compulsive SIB in the context of profound mental retardation." | 3.69 | Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. ( Davanzo, PA; King, BH, 1996) |
| "Lamotrigine is a new antiepileptic drug that may possess unique cognitive and behavioral characteristics." | 2.40 | Behavioral and cognitive effects of lamotrigine. ( Baker, GA; Meador, KJ, 1997) |
| "To study the risk of intellectual disability and delayed development in childhood milestones among children of women who used valproate or other AEDs during pregnancy." | 1.56 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. ( Christensen, J; Daugaard, CA; Dreier, JW; Pedersen, L; Sun, Y, 2020) |
| "However, seizures are not typical and the majority of them were seizure-free." | 1.51 | A 16q22.2-q23.1 deletion identified in a male infant with West syndrome. ( Goji, A; Imoto, I; Ito, H; Kagami, S; Kohmoto, T; Mori, K; Mori, T; Toda, Y, 2019) |
| "On VPA 1000 mg/d, the seizure frequency decreased significantly." | 1.37 | Valproate treatment after liver transplant in a patient with Lennox-Gastaut syndrome. ( Crespel, A; Gelisse, P; Genton, P; Pageaux, GP; Velizarova, R, 2011) |
| "The prevalence of unrecognized primary hypothyroidism and hyperthyroidism was 5·2% and 2·8%, respectively." | 1.37 | Thyroid status in a large cohort of patients with mental retardation: the TOP-R (Thyroid Origin of Psychomotor Retardation) study. ( de Rijke, YB; van Toor, H; Visser, TJ; Visser, WE, 2011) |
| "Falling due to startle-induced seizures (SISs) often leads to injury." | 1.37 | Lamotrigine is favourable for startle-induced seizures. ( Fujiwara, T; Ikeda, H; Imai, K; Inoue, Y; Shigematsu, H; Shishido, T; Takahashi, Y; Takayama, R, 2011) |
| "The syndrome is characterized by mental impairment, frequent seizures of multiple types that are particularly resistant to treatment, and high rates of seizure-related injury." | 1.36 | The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. ( Benedict, A; Maclaine, G; Verdian, L, 2010) |
| "Epilepsy is often the most important clinical manifestation of the syndrome, even if its appearance is not constantly precocious." | 1.35 | Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children. ( Canevini, MP; Dalla Bernardina, B; Darra, F; Fiorini, E; La Selva, L; Lazzarotto, F; Piazzini, A; Vignoli, A; Zucca, C, 2009) |
| "Epilepsy is a major comorbid condition in adolescents with mental retardation and is often characterized by multiple seizure types that are refractory to treatment." | 1.33 | Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuong, A, 2006) |
| "A 25-year-old girl with mild mental retardation had a 6-year history of absence seizures, with occasional head drop." | 1.31 | Mild generalized epilepsy and developmental disorder associated with large inv dup(15). ( Canevini, MP; Canger, R; Cavani, S; Chifari, R; Elia, M; Guerrini, R; Pierluigi, M; Sgrò, V, 2002) |
| "Mean lamotrigine dose was 272 +/- 133 mg per day." | 1.31 | Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. ( Gidal, BE; Lott, RS; Marty, KJ; Rutecki, P; Shaw, R; Speth, J; Walker, JK, 2000) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (41.94) | 18.2507 |
| 2000's | 8 (25.81) | 29.6817 |
| 2010's | 8 (25.81) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Bjørk, MH | 1 |
| Zoega, H | 1 |
| Leinonen, MK | 1 |
| Cohen, JM | 1 |
| Dreier, JW | 2 |
| Furu, K | 1 |
| Gilhus, NE | 1 |
| Gissler, M | 1 |
| Hálfdánarson, Ó | 1 |
| Igland, J | 1 |
| Sun, Y | 2 |
| Tomson, T | 1 |
| Alvestad, S | 1 |
| Christensen, J | 2 |
| Daugaard, CA | 1 |
| Pedersen, L | 1 |
| Mori, T | 1 |
| Goji, A | 1 |
| Toda, Y | 1 |
| Ito, H | 1 |
| Mori, K | 1 |
| Kohmoto, T | 1 |
| Imoto, I | 1 |
| Kagami, S | 1 |
| Orendi, K | 1 |
| Uhrig, S | 1 |
| Mach, M | 1 |
| Tschepper, P | 1 |
| Speicher, MR | 1 |
| Kubagawa, T | 1 |
| Furusho, J | 1 |
| Isozaki, Y | 1 |
| Carpay, JA | 1 |
| Aalbers, K | 1 |
| Graveland, GA | 1 |
| Engelsman, M | 1 |
| Vignoli, A | 1 |
| Canevini, MP | 2 |
| Darra, F | 1 |
| La Selva, L | 1 |
| Fiorini, E | 1 |
| Piazzini, A | 1 |
| Lazzarotto, F | 1 |
| Zucca, C | 1 |
| Dalla Bernardina, B | 1 |
| Benedict, A | 1 |
| Verdian, L | 1 |
| Maclaine, G | 1 |
| Velizarova, R | 1 |
| Gelisse, P | 1 |
| Pageaux, GP | 1 |
| Genton, P | 1 |
| Crespel, A | 1 |
| Visser, WE | 1 |
| de Rijke, YB | 1 |
| van Toor, H | 1 |
| Visser, TJ | 1 |
| Ikeda, H | 2 |
| Imai, K | 1 |
| Shigematsu, H | 1 |
| Shishido, T | 1 |
| Takayama, R | 1 |
| Fujiwara, T | 1 |
| Takahashi, Y | 1 |
| Inoue, Y | 1 |
| Adachi, M | 1 |
| Kawasaki, Y | 1 |
| Chifari, R | 1 |
| Guerrini, R | 1 |
| Pierluigi, M | 1 |
| Cavani, S | 1 |
| Sgrò, V | 1 |
| Elia, M | 1 |
| Canger, R | 1 |
| McKee, JR | 3 |
| Sunder, TR | 4 |
| FineSmith, R | 1 |
| Vuong, A | 2 |
| Varner, JA | 1 |
| Hammer, AE | 3 |
| Barrett, PS | 1 |
| Vuongc, A | 1 |
| Buchanan, N | 1 |
| Nadarajah, J | 1 |
| Duggan, L | 1 |
| Leary, PM | 1 |
| Allie, S | 1 |
| Uvebrant, P | 1 |
| Bauzienè, R | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Davanzo, PA | 1 |
| King, BH | 1 |
| Motte, J | 1 |
| Trevathan, E | 1 |
| Arvidsson, JF | 1 |
| Barrera, MN | 1 |
| Mullens, EL | 1 |
| Manasco, P | 1 |
| Meador, KJ | 1 |
| Baker, GA | 1 |
| Beran, RG | 1 |
| Gibson, RJ | 1 |
| Ettinger, AB | 1 |
| Weisbrot, DM | 1 |
| Saracco, J | 1 |
| Dhoon, A | 1 |
| Kanner, A | 1 |
| Devinsky, O | 1 |
| Besag, FM | 1 |
| Gidal, BE | 1 |
| Walker, JK | 1 |
| Lott, RS | 1 |
| Shaw, R | 1 |
| Speth, J | 1 |
| Marty, KJ | 1 |
| Rutecki, P | 1 |
| Crawford, P | 1 |
| Brown, S | 1 |
| Kerr, M | 1 |
| Pisani, F | 1 |
| Gallitto, G | 1 |
| Di Perri, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
4 reviews available for lamotrigine and Deficiency, Mental
| Article | Year |
|---|---|
Complete and pure trisomy 18p due to a complex chromosomal rearrangement in a male adult with mild intellectual disability.
Topics: Adult; Chromosomes, Human, Pair 18; Electroencephalography; Epilepsy; Face; Humans; Intellectual Dis | 2013 |
Meeting the challenge of epilepsy in persons with multiple handicaps.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Comorbidity; Developmental Disabilities | 1997 |
Behavioral and cognitive effects of lamotrigine.
Topics: Adult; Anticonvulsants; Child; Cognition Disorders; Epilepsy; Female; Humans; Intellectual Disabilit | 1997 |
Lamotrigine in the treatment of epilepsy in people with intellectual disability.
Topics: Anticonvulsants; Epilepsy; Humans; Intellectual Disability; Lamotrigine; Treatment Outcome; Triazine | 1998 |
4 trials available for lamotrigine and Deficiency, Mental
| Article | Year |
|---|---|
Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation.
Topics: Adolescent; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Intellectua | 2003 |
A new drug suitable for children and young people with epilepsy and intellectual impairments.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Intellectual | 1995 |
Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Epilepsy; Female; | 1997 |
A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administrati | 2001 |
23 other studies available for lamotrigine and Deficiency, Mental
| Article | Year |
|---|---|
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.
Topics: Anticonvulsants; Autism Spectrum Disorder; Autistic Disorder; Carbamazepine; Child; Cohort Studies; | 2022 |
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Denmark; Developmen | 2020 |
A 16q22.2-q23.1 deletion identified in a male infant with West syndrome.
Topics: Anticonvulsants; Chromosomes, Human, Pair 16; Epilepsy; Humans; Infant; Intellectual Disability; Lam | 2019 |
[Study of lamotrigine efficacy on behavior disorders affecting patients with severe mental retardation].
Topics: Adolescent; Adult; Anticonvulsants; Child; Epilepsy; Female; Humans; Intellectual Disability; Lamotr | 2015 |
Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Utilization Rev | 2009 |
Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children.
Topics: Adult; Age of Onset; Anticonvulsants; Child; Chromosomes, Human, Pair 20; Cognition Disorders; Comor | 2009 |
The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Computer Simulation; Cost-Benefit Analy | 2010 |
Valproate treatment after liver transplant in a patient with Lennox-Gastaut syndrome.
Topics: Anticonvulsants; Chemical and Drug Induced Liver Injury; Electroencephalography; Female; Fructose; H | 2011 |
Thyroid status in a large cohort of patients with mental retardation: the TOP-R (Thyroid Origin of Psychomotor Retardation) study.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Cohort Studies; Cross-Sectional Studies; Drug Therapy, | 2011 |
Lamotrigine is favourable for startle-induced seizures.
Topics: Activities of Daily Living; Age of Onset; Anticonvulsants; Atrophy; Brain; Child; Drug Eruptions; El | 2011 |
[The effects of lamotrigine on refractory epilepsies in persons with severe motor and intellectual disabilities].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Fe | 2012 |
Mild generalized epilepsy and developmental disorder associated with large inv dup(15).
Topics: Adult; Age of Onset; Angelman Syndrome; Anticonvulsants; Chromosome Aberrations; Chromosome Inversio | 2002 |
Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation.
Topics: Activities of Daily Living; Adolescent; Adult; Anticonvulsants; Drug Tolerance; Epilepsy; Female; Hu | 2006 |
Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation.
Topics: Adolescent; Adolescent Behavior; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female | 2006 |
The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability.
Topics: Activities of Daily Living; Adolescent; Adult; Anticonvulsants; Brain Damage, Chronic; Child; Child, | 1995 |
A missed diagnosis. A missed opportunity for community integration.
Topics: Adult; Anticonvulsants; Combined Modality Therapy; Diagnosis, Differential; Electroencephalography; | 1995 |
Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Attention; Autistic Disorder; Brain; Child; Child, | 1994 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Epilepsy; Fear; Female; Follow-Up Studies; Humans; Intel | 1996 |
Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine.
Topics: Adolescent; Adult; Aggression; Anticonvulsants; Comorbidity; Drug Administration Schedule; Epilepsy; | 1998 |
Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation.
Topics: Adolescent; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Follow-Up Studies; | 1998 |
Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation.
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Female; Humans; I | 2000 |
Could lamotrigine be useful in status epilepticus? A case report.
Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Female; Human | 1991 |